Ronan Hsieh, MD, MS
@ronanhsieh
Followers
499
Following
453
Statuses
538
Assistant Professor & GI oncologist at University of Washington Fred Hutchinson Cancer Center. Trials/early phase/AI/ML. GI cancers. @swog @fredhutch @uw
Seattle, WA
Joined September 2010
RT @josephjzhao: Sex and outcomes of patients with microsatellite instability-high and BRAF V600E mutated metastatic colorectal cancer rece…
0
4
0
RT @GIMedOnc: Gastric + Gastroesophageal Adeno Exciting (negative) trial Adjuvant Nivo + Ipi for patients with high risk of recurrence af…
0
2
0
RT @CharlesJiangMD: Fellow oncologists – check out my free visualization tool for adjuvant therapy risks & benefit discussion. It's built f…
0
15
0
RT @ArndtVogel: Trial of Gemcitabine, Cisplatin & Nab-Paclitaxel vs Gemcitabine/ Cisplatin in BTC @JCO_ASCO 🔎SWOG…
0
24
0
RT @ArndtVogel: Tiragolumab in combination with atezolizumab + bevacizumab in advanced or metastatic HCC @TheLancetOncol
0
41
0
RT @ArndtVogel: Efficacy of Zenocutuzumab in NRG1 Fusion–Positive Cancer @NEJM 🔎Ph2-2, 204 pts, 12 tumor types 👉 b…
0
17
0
RT @mdmanishshah: Amazing meeting @ASCO #GIASCO and really nice to help provide updates for @eChinaHealth
@WeillCornell @WCM_GI @nyph…
0
1
0
RT @Erman_Akkus: 🧬DDR mutations and outcome in biliary tract cancers @JournalCancer ➡️DDR-positive vs. DDR-negative ✅With platinum-based…
0
14
0
It is published! So honored to be a co-author in this article discussing the importance of ctDNA in CRC.
✳️Our paper discussing the role of ctDNA for the management of patients with early stage colon is now out ‼️ ✳️CtDNA is rapidly evolving and it is here to stay ❗️In this article we discussed the pros and cons of ctDNA and it is relevance to personalized adjuvant therapy ❗️Here are some key points👇 @drjkyl @TCRT_Cancer @OncoDailyGI @oncodaily @manjuggm @CrcTrialsChat
1
1
11
RT @ArndtVogel: Encorafenib, cetuximab and chemotherapy in BRAF-mutant colorectal cancer: @NatureMedicine 🔎BREAKWA…
0
47
0
Congratulations Amy! She was awarded a merit award in ASCO GI for this study.
➡️ #ASCOGI25 Our merit award-winning meta-analysis on EGFRi rechallenge for metastatic colorectal cancer: 🔴 EGFRi rechallenge: significantly ⬆️ PFS than EGFRi-free systemic therapy, esp. for RAS/RAF-wild type mCRC Mentor @ronanhsieh
@fredhutch
@UConn
@DanaFarber
@cityofhope
1
0
8
RT @OncBrothers: #TDXd now @US_FDA approved based off DB06: Ph III, TDXd vs chemo in endocrine resistant HR+ HER2 low and HER2-ultralow -…
0
47
0
RT @Erman_Akkus: 💉Adding Tiraglumab to Atezo-Beva in 1L of HCC MORPHEUS-Liver @TheLancetOncol ➡️ anti-TIGIT, phase 1b–2 ✅ORR: 43% vs. 11…
0
30
0
RT @KoheiShitara: Pleased to share P2 results of futibatinib for FGFR2-amplified gastric cancer: ORR 17.9%. Shows some activity but undersc…
0
10
0
RT @TsungCheWu: #GI25 Checkmate 8HW: dMMR/MSI-H CRC 1L 3Y PFS: Nivo/Ipi 68% vs Nivo 51% (HR 0.62). Groundbreaking—best 3Y PFS in any phase…
0
1
0
RT @CathyEngMD: Post hoc analysis of CALGB 80702 in stage III ctDNA (+), with improved DFS following celebrex x 3 yrs, DFS HR = 0.55 as p…
0
16
0
RT @pashtoonkasi: @TheLancet @OncoAlert One thing that I didn’t notice till the Q&A 🎙️ is that this immunotherapy comparison of NIVO 🆚 IPI/…
0
1
0